M&A: Page 2

Boston Scientific bets on cardiac wearables with $925M Preventice buy

The deal is the latest in the fast-growing space, coming on the heels of Hillrom's $375 million BardyDx buy on Tuesday and Philips' $2.8 billion purchase of BioTelemetry last month.

By Ricky Zipp • Jan. 21, 2021

Haemonetics inks $510M Cardiva takeover to expand hospital business

The blood products medtech contends the deal will strengthen its portfolio in interventional cardiology and electrophysiology markets.

By Nick Paul Taylor • Jan. 21, 2021

Explore the Trendline➔

Trendline

The MedTech Dive Outlook on 2021

The pandemic will keep disrupting the industry in the year ahead, as COVID-19 testing wanes and elective procedures slowly ease back. We look at the risks, challenges and opportunities.

By MedTech Dive staff

Hillrom makes cardiac monitoring play with $375M BardyDx buy

The deal fits Hillrom's existing heart portfolio and efforts to connect devices to the internet, analysts said, but one raised concerns about Medicare reimbursement.

By Susan Kelly • Jan. 20, 2021

Thermo Fisher buys Mesa Biotech for $450M to bolster rapid point-of-care testing

The all-cash acquisition, which includes the potential for an additional $100 million upon completion of milestones, adds Mesa's PCR test platform for SARS-CoV-2, influenza A and B, RSV and strep A to Thermo's portfolio.

By Greg Slabodkin • Jan. 19, 2021

Philips to acquire Capsule Technologies in $635M deal, growing patient data capabilities

The move follows the medtech giant's $2.8 billion acquisition of cardiac monitoring company BioTelemetry in December, one of 2020's largest deals.

By Ricky Zipp • Jan. 19, 2021

Pandemic propels health systems to mull insurer acquisitions, partnerships: JPM21

Advocate Aurora CEO Jim Skogsbergh said "partnering for health plan capability is going to be critical to our success."

By Samantha Liss • Jan. 14, 2021

Steris inks $4.6B buy of Cantel Medical amid flurry of M&A

It's the biggest deal so far this year. Wall Street analysts said COVID-19 infection concerns should boost Cantel in the long term.

By Ricky Zipp • Jan. 13, 2021

Healthcare CFOs see fresh wave of M&A in 2021: BDO poll

Financial distress, a desire to expand into new service lines and efforts to close infrastructure gaps are expected to fuel the upturn, according to the consultants.

By Susan Kelly • Jan. 12, 2021

Medtech M&A to take off after pandemic slowed deals in 2020: EY

Dealmaking in 2021 will be fueled by financial firepower across the industry at an "all-time high" of nearly $500 billion, according to the consultants.

By Ricky Zipp • Jan. 10, 2021

PerkinElmer inks $591M Oxford Immunotec buy to challenge Qiagen in TB market

The deal comes amid a flurry of medtech M&A during the first week of 2021. Hologic inked two acquisitions in the women's health space and Stryker said it would buy sensor maker OrthoSensor.

By Nick Paul Taylor • Jan. 08, 2021

Hologic's $230M Biotheranostics buy its 2nd M&A deal of 2021

Some Wall Street analysts were surprised by the target, but others suggested the move could strengthen the company for a post-coronavirus environment.

By Ricky Zipp • Jan. 06, 2021

Stryker buys sensor maker in bet on wearables in orthopaedics

OrthoSensor's technology could complement the medtech's robotics platform and boost its data analytics capabilities, SVB Leerink analysts said in a Tuesday note on the acquisition.

By Susan Kelly • Jan. 05, 2021

Hologic eyes future post COVID-19 with Somatex Medical tuck-in

The medical device maker is bulking up its women's health business as molecular diagnostics sales surge due to the pandemic. Wall Street analysts have said these lines are equipped to withstand market uncertainties.

By Susan Kelly • Jan. 05, 2021

The top medtech deals of 2020 (and one that got away)

M&A activity bounced back in the second half of the year, with deals ranging from Teladoc's $18.5 billion Livongo buy to Stryker's drawn-out $4 billion acquisition of Wright Medical.

By Susan Kelly • Jan. 04, 2021

Hospital giant Tenet goes big on ASCs

A shift in focus to outpatient settings is also occurring among medical device companies. Both Stryker and Zimmer Biomet have made ASCs more of a priority over the last several years.

By Samantha Liss • Dec. 22, 2020

Philips buys cardiac monitoring company BioTelemetry in $2.8B deal

The Dutch conglomerate said that the move will expand its remote patient monitoring business beyond the hospital space. Baird called the pact a surprise but the valuation fair.

By Ricky Zipp • Dec. 18, 2020

Olympus to pay $300M to buy Veran for lung navigation system

The deal is for $300 million up front, with another $40 million tied to an undisclosed milestone.

By Nick Paul Taylor • Dec. 07, 2020

LivaNova offloads heart valve tech to Gyrus Capital following investor pressure

The announcement comes shortly after activist shareholder PrimeStone Capital demanded LivaNova sell or close the "likely loss-making" business line.

By Maria Rachal • Dec. 03, 2020

Zimmer puts up $250M in surgical device deal, Boston Scientific nets $800M in BTG pharma sell-off

The pandemic hasn't stopped M&A in the medtech industry, with Zimmer Biomet adding to its sternal closure device lineup via A&E Medical and Boston Scientific streamlining business with a sale to specialty pharma group SERB.

By Nick Paul Taylor • Dec. 01, 2020

Healthcare deals in Q4 predicted to fall from record-setting Q3: report

Market research firm CB Insights believes the drop will carry over into the digital health sector too, an area that's seen historic investor interest in 2020 amid the coronavirus pandemic.

By Rebecca Pifer • Nov. 25, 2020

Zimmer reports record robot installs, ASC-inspired M&A

While the company benefited from a rebound in elective procedures, execs warned investors the recovery slowed as the third quarter drew to a close.

By Nick Paul Taylor • Nov. 06, 2020

Stryker closes Wright Medical acquisition after year-long wait

The Kalamazoo, Michigan-based medtech highlighted the shoulder, elbow, wrist, hand, foot and ankle devices it's gained, along with preoperative planning technology, now that the deal is final.

By Maria Rachal • UPDATED: Nov. 11, 2020 at 8:48 a.m.

Illumina defends Grail valuation amid much cheaper Exact-Thrive deal

The biotech defended its $8 billion purchase price against Exact Sciences' $2.15 billion cancer screening takeout agreement announced this week, arguing Grail has more data and is likely to be first to market.

By Nick Paul Taylor • Oct. 30, 2020

Medtronic acquires thyroid surgery tech in 7th tuck-in deal of 2020

An addition to the medtech's pandemic-battered ENT business, Ai Biomed's PTeye system won De Novo authorization from FDA in 2018 for its ability to help surgeons spare important calcium-regulating tissue during procedures.

By Maria Rachal • Oct. 29, 2020

Teleflex lines up $525M to buy hemostat specialist Z-Medica

The medtech predicts the trauma surgery and emergency medicine-focused products will begin adding up to $70 million in revenue next year, providing growth drivers outside its key interventional urology segment.

By Maria Rachal • Oct. 29, 2020